Neumora Therapeutics, Inc. — All Filings
226 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
424B4
8-A12B
8-K
8-K/A
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
POS AM
POSASR
PRE 14A
S-1
S-1/A
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | — | 0001610717-26-000054 | Feb 19, 2026 | Feb 17, 2026 |
| 4 | — | 0001610717-26-000053 | Feb 19, 2026 | Feb 17, 2026 |
| 4 | — | 0001610717-26-000052 | Feb 19, 2026 | Feb 17, 2026 |
| 4 | — | 0001610717-26-000051 | Feb 19, 2026 | Feb 17, 2026 |
| SCHEDULE 13G | — | 0002005369-26-000014 | Feb 19, 2026 | — |
| SCHEDULE 13G/A | — | 0000905148-26-000895 | Feb 17, 2026 | — |
| 144 | — | 0001964306-26-000112 | Feb 17, 2026 | — |
| 144 | — | 0001964306-26-000111 | Feb 17, 2026 | — |
| 144 | — | 0001964306-26-000110 | Feb 17, 2026 | — |
| 144 | — | 0001964306-26-000109 | Feb 17, 2026 | — |
| 8-K | 8-K | 0001193125-26-045526 | Feb 11, 2026 | — |
| 8-K | 8-K | 0001193125-26-009727 | Jan 12, 2026 | — |
| 4 | — | 0001610717-26-000010 | Jan 9, 2026 | Jan 8, 2026 |
| 4 | — | 0001610717-26-000009 | Jan 9, 2026 | Jan 8, 2026 |
| 4 | — | 0001610717-26-000014 | Jan 9, 2026 | Jan 8, 2026 |
| 4 | — | 0001610717-26-000011 | Jan 9, 2026 | Jan 8, 2026 |
| 4 | — | 0001610717-26-000008 | Jan 9, 2026 | Jan 8, 2026 |
| 8-K | 8-K | 0001193125-26-001472 | Jan 5, 2026 | — |
| 8-K | 8-K | 0001193125-25-291352 | Nov 21, 2025 | Nov 17, 2025 |
| 4 | — | 0001610717-25-000378 | Nov 13, 2025 | Nov 11, 2025 |
| 144 | — | 0001628280-25-051788 | Nov 12, 2025 | — |
| 10-Q | 10-Q | 0001193125-25-269446 | Nov 6, 2025 | Sep 30, 2025 |
| 8-K | 8-K | 0001193125-25-268046 | Nov 6, 2025 | — |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001012975-25-000681 | Oct 29, 2025 | Oct 27, 2025 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001012975-25-000680 | Oct 29, 2025 | Oct 27, 2025 |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001012975-25-000679 | Oct 29, 2025 | Oct 27, 2025 |
| SCHEDULE 13D/A | — | 0001012975-25-000675 | Oct 29, 2025 | — |
| 8-K | 8-K | 0001193125-25-250677 | Oct 27, 2025 | — |
| 8-K | 8-K | 0001193125-25-250656 | Oct 27, 2025 | — |
| SCHEDULE 13G | — | 0000905148-25-002815 | Aug 11, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-104138 | Aug 6, 2025 | Jun 30, 2025 |
| 8-K | 8-K | 0000950170-25-103997 | Aug 6, 2025 | — |
| 4 | 4 | 0000950170-25-079926 | May 30, 2025 | May 28, 2025 |
| 4 | 4 | 0000950170-25-079924 | May 30, 2025 | May 28, 2025 |
| 4 | 4 | 0000950170-25-079925 | May 30, 2025 | May 28, 2025 |
| 4 | 4 | 0000950170-25-079923 | May 30, 2025 | May 28, 2025 |
| 4 | 4 | 0000950170-25-079922 | May 30, 2025 | May 28, 2025 |
| 4 | 4 | 0000950170-25-079921 | May 30, 2025 | May 28, 2025 |
| 4 | 4 | 0000950170-25-079920 | May 30, 2025 | May 28, 2025 |
| 4 | 4 | 0000950170-25-079919 | May 30, 2025 | May 28, 2025 |
| 4 | 4 | 0000950170-25-079918 | May 30, 2025 | May 28, 2025 |
| 4 | 4 | 0000950170-25-079908 | May 30, 2025 | May 28, 2025 |
| 8-K | 8-K | 0001193125-25-132307 | May 30, 2025 | May 28, 2025 |
| 4 | — | 0001610717-25-000128 | May 23, 2025 | May 21, 2025 |
| DEFA14A | DEFA14A | 0001193125-25-121717 | May 16, 2025 | — |
| 8-K | 8-K | 0001193125-25-121714 | May 16, 2025 | May 14, 2025 |
| 10-Q | 10-Q | 0000950170-25-069311 | May 12, 2025 | Mar 31, 2025 |
| 8-K | 8-K | 0000950170-25-069147 | May 12, 2025 | — |
| SCHEDULE 13G/A | — | 0000315066-25-001531 | May 12, 2025 | — |
| DEFA14A | DEFA14A | 0000950170-25-060098 | Apr 29, 2025 | — |